Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
UBS
Dow
Merck
QuintilesIMS
Julphar
Baxter
Harvard Business School
AstraZeneca

Generated: February 19, 2019

DrugPatentWatch Database Preview

EYLEA Drug Profile

« Back to Dashboard

Summary for Tradename: EYLEA

US Patents for EYLEA

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Patent Expiration Status Orphan Source
Regeneron Pharmaceuticals EYLEA aflibercept INJECTABLE; INJECTION 125387 001 2011-11-18 ➤ Sign Up Avalanche Australia Pty Ltd. (Southbank, AU) ➤ Sign Up RX search
Regeneron Pharmaceuticals EYLEA aflibercept INJECTABLE; INJECTION 125387 001 2011-11-18 ➤ Sign Up ➤ Sign Up RX search
Regeneron Pharmaceuticals EYLEA aflibercept INJECTABLE; INJECTION 125387 001 2011-11-18 ➤ Sign Up King Fahd University of Petroleum and Minerals (Dhahran, SA) King Saud University (Riyadh, SA) ➤ Sign Up RX search
Regeneron Pharmaceuticals EYLEA aflibercept INJECTABLE; INJECTION 125387 001 2011-11-18 ➤ Sign Up STC.UNM (Albuquerque, NM) ➤ Sign Up RX search
Regeneron Pharmaceuticals EYLEA aflibercept INJECTABLE; INJECTION 125387 001 2011-11-18 ➤ Sign Up King Fahd University of Petroleum and Minerals (Dhahran, SA) King Saud University (Riyadh, SA) ➤ Sign Up RX search
Regeneron Pharmaceuticals EYLEA aflibercept INJECTABLE; INJECTION 125387 001 2011-11-18 ➤ Sign Up NOVARTIS AG (Basel, CH) ➤ Sign Up RX search
Regeneron Pharmaceuticals EYLEA aflibercept INJECTABLE; INJECTION 125387 001 2011-11-18 ➤ Sign Up CureVac AG (Tubingen, DE) ➤ Sign Up RX search
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Patent Expiration Status Orphan Source

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for EYLEA

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
CR 2013 00020 Denmark ➤ Sign Up PRODUCT NAME: AFLIBERCEPT; REG. NO/DATE: EU/1/797/001-002 20121122
C01183353/01 Switzerland ➤ Sign Up PRODUCT NAME: AFLIBERCEPT; REGISTRATION NO/DATE: SWISSMEDIC 62397 29.10.2012
500 Finland ➤ Sign Up
PA2013009 Lithuania ➤ Sign Up PRODUCT NAME: AFLIBERCEPTUM; REGISTRATION NO/DATE: EU/1/12/797/001, 2012 11 22 EU/1/12/797/002, 2012 11 22 EU/1/12/814 20130201
2013/016 Ireland ➤ Sign Up PRODUCT NAME: AFLIBERCEPT; REGISTRATION NO/DATE: EU/1/12/797/001-002 20121122
C300588 Netherlands ➤ Sign Up PRODUCT NAME: AFLIBERCEPT; REGISTRATION NO/DATE: EU/1/12/797/001-002 20121122
122013000041 Germany ➤ Sign Up PRODUCT NAME: AFLIBERCEPT; REGISTRATION NO/DATE: EU/1/12/797/001-002 20121122
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Healthtrust
Accenture
Cerilliant
Express Scripts
Harvard Business School
AstraZeneca
Chinese Patent Office
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.